ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

DEMG Deltex Medical Group Plc

0.1025
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Deltex Medical Group Plc LSE:DEMG London Ordinary Share GB0059337583 ORD 0.01P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.1025 0.10 0.105 0.1025 0.1025 0.10 629,019 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Electromedical Apparatus 2.48M -1.15M -0.0006 -1.67 1.85M
Deltex Medical Group Plc is listed in the Electromedical Apparatus sector of the London Stock Exchange with ticker DEMG. The last closing price for Deltex Medical was 0.10p. Over the last year, Deltex Medical shares have traded in a share price range of 0.1025p to 1.55p.

Deltex Medical currently has 1,846,653,348 shares in issue. The market capitalisation of Deltex Medical is £1.85 million. Deltex Medical has a price to earnings ratio (PE ratio) of -1.67.

Deltex Medical Share Discussion Threads

Showing 20626 to 20649 of 22600 messages
Chat Pages: Latest  832  831  830  829  828  827  826  825  824  823  822  821  Older
DateSubjectAuthorDiscuss
18/9/2019
16:29
Great move today on virtually no volume. Just imagine what might happen if we get a big volume day either in the next 2 days or on results day!
nobbygnome
18/9/2019
11:41
Going up nicely on not much volume.
janatha
17/9/2019
08:00
Positive results would be somewhat better than negative ones but the near future ought to be a sale of the company at a value comparable to that achieved by CheetahAs well as confirmation that the company is trading cash positively, it would be good to hear about growth in second half and progress with non invasive Doppler and the new multi-modal monitorBut it would be best to hear either that the current BOD is getting on with an exit or bringing in fresh faces to get that job done. New brokers would be a positive step too
mrc2u
17/9/2019
07:31
It really does appear that some have forgotten what this company actually do.

The tech is really nothing new - the have been peddling the same stuff for many many years without success

It is not suddenly going to turn around

trentendboy
16/9/2019
21:55
Nobbygnome
16 Sep '19 - 15:29 - 10357 of 10359

Because DEMG has to produce some positive results, half after half.

bigt20
16/9/2019
15:25
There isn't that much on offer on the RSP so it won't take much buying to get the price moving north. I am toying with the idea of getting another 500k....
nobbygnome
16/9/2019
14:40
Nobby there will be people that bought at 1p and we're hoping for it to be a little higher than it is now, 3 million share isn't really a big deal although it did knock the Sp, only 3/4 months ago we were 1.80- 2p and will be again, you need a lot of patience with DEMG. I keep repeating it but the mms do nothing to attract buyers, their failure to ask for the full ask is bordering on fraudulent, just look @ the buy trades all were below the full ask last Thu or Fri I think it was.
gbenson1
16/9/2019
14:29
So why is the market so out of kilter with reality here and why was someone willing to sell 3 million at 1.2p or below just over a week ago? Surely this is an absolute screaming buy now......but no one is buying.
nobbygnome
16/9/2019
14:15
I'm hoping the Vizient tie-up will get us noticed more in the US, I think Michael Stubbs is well aware of this hence his share building. With the NHS/UK sales stalling we need to push sales and awareness of our proven devices in the USA & Worldwide.
gbenson1
16/9/2019
13:54
Until last week I thought 3 times turnover (3p) about right

Given that loss making and cash consuming Cheetah just got bought for around 12.5 times turnover and about 40 times consumable turnover, I think these should be a lot higher than any of 2.0p or 2.5p or 3.0. 5p to 7p would be more like it and still need a very hefty control premium from an acquirer to get to a reasonable comparable

Remember that the Cheetah deal makes it far more likely that there will be potential buyers sniffing around

schloo
16/9/2019
12:56
For me at least 2 times turnover is a fair valuation so that's around 2p. So why on earth are we languishing at 1.275p...... Complete madness! The upcoming results should highlight the sustainability of the cash flow positivity and so could be the catalyst for a rerating.
nobbygnome
16/9/2019
12:37
Thanks for the info schloo, and assume with a healthy balance sheet we should have a Sp around the 2.5p mark?
gbenson1
16/9/2019
12:11
Agreed although I don't think acquirers will be that bothered by the balance sheet. Cheetah never generated any cash and Baxter still paid a very high price

Cheetah raised $12m of equity in 2017 and $7m more in 2018, none of it from new investors, suggesting it was a struggle. They then raised another $20m in venture debt earlier this year so balance sheet can not be pretty

For DEMG, as a listed company whereas Cheetah was private, the key point about being cash flow positive is that there is no longer any incentive for the market to massively undervalue the company in anticipation of buying new shares super cheap in a placing

The Cheetah deal shows that someone might well be willing to pay big money for DEMG right now, but it simply won't happen until the share price gets to a half sensible place. No reason, now its cash positive, why that should not happen now either

schloo
16/9/2019
11:22
I think valuing DEMG is obviously a difficult job, I feel we need to have a strong balance sheet over the next 12-18 months, then maybe on of the larger players might well have a figure in the range of £56-70m but it's only worth what someone is willing to pay for it!!
gbenson1
16/9/2019
11:10
Schloo

Cheers. Good input.

janatha
16/9/2019
10:38
>> schloo

So how much do you think Edwards would pay for DEMG..... Seems to me that we are heading towards an inevitable conclusion sooner or later although I accept it may be later rather than sooner!

nobbygnome
16/9/2019
10:31
Cheetah's technology is bio-impedance based. You put electrodes above and below the heart and run a current between them then measure the disruption to that current when the chest fills with blood with the heart pumpingIt is not as accurate as ODM because it is measuring flow indirectly rather than directly but is superior to the Edwards & Lidco approaches which do not measure flow at all but instead try to derive it from pressure. Like them, and unlike DEMG, Cheetah have struggled to build an evidence base of clinical benefitHowever the technology is entirely non-invasive, easy to use and plenty good enough for monitoring cardiac output and basic interventionsBUT it is not relevant which is the better technology between ODM or impedance. Baxter have bought Cheetah and will throw tens or hundreds of million at marketing it. The question ought to be who is going to compete with them and howIt could be Edwards who will need to respond to Baxter parking the tanks on their lawn. It could be any of the other big fluid companies such as Fresenius or B Braun. It could be any major medtech company looking for a potentially massive new market. It could be Getinge who bought PulsionAt least one of them ought to focus on DEMG not just because it has the best technology for getting results, but also because it also sells the same technology as Edwards, Lidco & Pulsion and, to cap it all, it also sells a superior version of the cheetah technology
schloo
16/9/2019
09:28
--->ALL

I don't understand this obsession with individual trades.

It's all just a drop in the ocean as hundreds of millions of shares are now in issue. A couple of million here and there really are pretty insignificant.

Regards,

THE COUNT!

the count
16/9/2019
06:42
Well the fall from 1.4 to 1.2 was on the back of an apparent forced seller of 3 million shares. More than that have now been bought since the fall so a rise back to 1.4 seems nailed on to me. Then it depends how positive the outlook statement is about ongoing cash flow positivity. We know July was good so it really is about August which is I suspect the quietest month.
nobbygnome
16/9/2019
06:34
Well only 7 days to the interim results, buy volume has picked up quite recently, let's see how the Sp reacts this week. Anyone care to make any predictions?
gbenson1
13/9/2019
22:00
edited my post as nobby has mentioned the possible effect of options being exercised (which is what I was going to say)


BTW. good luck trying to understand MM's

bigt20
13/9/2019
14:04
The mms here are reluctant to ask for the full ask, they drop the Sp on low volume and fail the raise the Sp on larger volume. On a good day they do raise the Sp but it normally falls back throughout the day. Welcome to AIM.
gbenson1
13/9/2019
14:03
Nobby (post 10339), I too haven't looked at the numbers, but I expect you are right.
gnnmartin
13/9/2019
13:57
And I forgot about the 550k bought after the fall on Friday so net 750k bought and the price is down 10%.....
nobbygnome
Chat Pages: Latest  832  831  830  829  828  827  826  825  824  823  822  821  Older

Your Recent History

Delayed Upgrade Clock